Pressemeddelelse

Västra Hamnen Market Focus: Gabather: Starting phase II clinical trial

  • Approval to initiate the financed TOTEMS study
  • Patient enrolment imminent

Gabather has announced the initiation of the TOTEMS study, a phase II clinical trial evaluating the drug candidate GT-002 in patients with schizophrenia spectrum disorders. The study is conducted at the Center for Neuropsychiatric Schizophrenia Research (CNSR) at the Copenhagen University Hospital. Positive preliminary results would be a great boon to the investment case, for now we wait patiently.

The full report is available here.